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A model of antibiotic synergy based on a molecular mechanism ofaction which blocked sequential steps in
a single metabolic pathway was tested. Twenty-five strains each of Pseudomonas, Klebsiella, and Serratia
were tested in vitro against three different two drug combinations of vancomycin, carbenicillin, or cephal-
othin. Synergy was observed when vancomycin was combined with either carbenicillin orcephalothin against
isolates of Pseudomonas or Serratia, whereas the combination ofcarbenicillin and cephalothin did not result
in significant synergy against these isolates. The presence of synergy was not related to the sensitivity or
resistance of the isolates to the drugs in the combination. Synergy was also observed with all three antibiotic
combinations against Klebsiella isolates which may be related to enzyme inactivation by one of the drugs in
the combination. These observations support the hypothetical model ofantibiotic synergy based on sequen-
tial blocking of one biochemical pathway.
INTRODUCTION
The principles of antibiotic synergy were discussed over twenty years ago [1], but
the development of synergistic combinations was often based on experimental trials
rather than theoretical grounds. Much has been learned during the past twenty years
about the molecular mechanisms of antibiotic action. These earlier studies have
provided an opportunity to possibly predict and to develop, on theoretical grounds,
synergistic combinations of antimicrobial agents.
The present investigation was undertaken in an attempt to test a theoretical model
of antibiotic synergy by selecting combinations ofantibiotics that theoretically have
the potential for synergistic activity and comparing these combinations with other
drug combinations that theoretically should not act synergistically. The theoretical
model tested was that of sequential antibiotic action. Specifically, the model postu-
lates that synergy can be obtained by using two different antibiotics with molecular
mechanisms ofaction which block different steps in a single metabolic pathway ofthe
organism. The activity of such antibiotic combinations was compared with a two
drug antibiotic combination with molecular mechanisms ofaction which potentially
blocked the same site in the same metabolic pathway of the organism.
The antibiotics used were vancomycin, carbenicillin, and cephalothin which are all
cell wall synthesis inhibitors. These antibiotics were tested in vitro, singly and in
combination with each other, against Pseudomonas aeruginosa, Klebsiellapneumo-
niae, and Serratia marcescens. The combination ofvancomycin and carbenicillin, as
well as that ofvancomycin and cephalothin theoretically act sequentially, whereas the
combination ofcarbenicillin and cephalothin theoretically acts at the same metabolic
site (Fig. 1). The use ofthese antibiotics and bacterial strains permitted an extensive
test of the synergy model since vancomycin alone has little, if any, antibacterial
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activity against the gram-negative bacilli used in the present study [2], carbenicillin,
though effective against strains of pseudomonas [3], has intermediate activity against
Serratia marcescens [4] and virtually no activity against klebsiella species [5], and
cephalothin, though effective against klebsiella species, has no activity against strains
of pseudomonas or Serratia marcescens [6].
MATERIALS AND METHODS
Bacterial Strains. Twenty-five strains each of Pseudomonas aeruginosa, Klebsiella
pneumoniae and Serratia marcescens were obtained from clinical isolates. These
bacterial strains were identified by the Yale-New Haven Hospital Clinical Microbiol-
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ogy Laboratory and were subcultured and reidentified in our Research Laboratory as
previously described [3].
Antibiotics. All antibiotics were kindly supplied as laboratory standards by their
manufacturers. Vancomycin as vancomycin sulfate and cephalothin as the sodium
salt were supplied by Eli Lilly and Company, Indianapolis, Indiana, and carbenicillin
was supplied by Roerig, New York, New York. Stock solutions ofvancomycin and
carbenicillin were made up in normal saline and distilled water respectively. The
cephalothin laboratory standard was used for concentrations less than 1000 ug/ml
and sodium cephalothin intravenous injection grade was used for concentrations
greater than 1000 ug/ml. Cephalothin stock solutions were made up in pH 6.0
potassium-phosphate buffer and were used on the same day. Stock solutions of
vancomycin and carbenicillin were stored at .40C for up to one month.
In Vitro Testing. All studies were done using Mueller-Hinton Broth (BBL Inc.,
Cockeysville, Md.). This broth was chosen because of its use with agar in disc
sensitivity testing and because of its reproducibility from batch to batch [7]. All tests
of synergy were done in vitro using an Autotiter III microdilution system (Canalco
Inc., Rockville, Md.) and plastic trays with grids of wells in a manner previously
described [3]. The inoculum used was between 1-5 x 105 organisms/ml and the
incubation time was 22-24 hours at 370C and maximum humidity. At the end ofthe
incubation period, each tray was read visually for the pattern of bacterial growth (as
turbidity) in the wells. Each bacterial strain was tested in triplicate foreach antibiotic
combination stocked and the results were recorded only if at least two trays had
identical patterns.
Definitions. As previously described [3] the patterns of growth and inhibition of
growth were interpreted for each test as follows:
Synergy. No growth of bacteria in the presence of two antibiotics, each ofwhich is
present at a concentration which is less than 1/2 of its minimal inhibitory concentra-
tion (MIC).
Partial Synergy. No growth of bacteria in the presence of two antibiotics, one of
which is present at a concentration less than 1/2 of its MIC and the other ofwhich is
present at a concentration which is ½2 of its MIC.
Additive. No growth of bacteria in the presence oftwo antibiotics, each ofwhich is
present at a concentration which is 1/2 of its MIC.
Indifferent. No inhibition of growth in the presence of two antibiotics, each of
which is present at ½2 of its MIC.
Partial Antagonism. No inhibition of growth in the presence of two antibiotics
when one of the antibiotics is present in a concentration at least that of its MIC and
the other is present at a concentration less than its MIC.
Analysis. The significance of differences in the incidence of synergy (including
partial synergy) between two antibiotic combinations was measured using Fishers
Test [8]. Due to the distribution of results over several categories, synergistic and
partially synergistic results were combined in the analysis and compared together
against additive and indifferent results.
RESULTS
The minimum inhibitory concentrations of vancomycin, carbenicillin and cephal-
othin when tested alone against twenty-five strains each ofPseudomonas aeruginosa,
Klebsiella pneumoniae and Serratia marcescens are listed in Table 1. None of the
organisms tested could be inhibited by vancomycin in concentrations less than 1250
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TABLE 1
Minimum Inhibitory Concentrations (MIC)
of Vancomycin, Carbenicillin and Cephalothin for
Pseudomonas, Klebsiella and Serratia Isolates
Antibiotic Pseudomonas Klebsiella Serratia
(ug(ml) (No. strains) (No. strains) (No. strains)
Vancomycin
1250
2500
>5000
Carbenicillin
0.625
2.5
5.0
7.8
15.6
31.2
62.5
125
250
500
2,000
2,500
5,000
8,000
10,000
Cephalothin
3.12
6.25
12.5
>1,600
5,000
>5,000
10,000
6
19
25 4
16
S
2
4
2
3
l 14
7
4
4
10
l
4
6
9
8
S
3
21
4
2
4
7
2
23
ug/ml. Carbenicillin inhibited the strains of pseudomonas at concentrations between
15.6 and 62.5 ug/ml. Klebsiella isolates were more resistant and required concentra-
tions ofcarbenicillin between 125 and 8000 ug/ml. Isolates ofSerratia marcescens fell
into two groups, those which were inhibited by concentrations of carbenicillin
between 0.625 and 15.6 ug/ml and a resistant group which required between 2500 and
10,000 ug/ml. Cephalothin inhibited most Klebsiella isolates at concentrations of
12.5 ug/ml or less whereas isolates of Pseudomonas and Serratia were highly
resistant and were only inhibited by concentrations of 5000 to 10,000 ug/ml.
A synergistic effect between vancomycin and carbenicillin was observed in the
majority (19 of 25) of isolates of Pseudomonas aeruginosa (Fig. 2). Similarly, the
combination of vancomycin and cephalothin was synergistic for 12 ofthe 25 Pseudo-
monas isolates. In contrast, the combination of carbenicillin and cephalothin pro-
duced a synergistic effect in only 4 of the 25 Pseudomonas isolates. The combination
of vancomycin and carbenicillin, each of which alone had little effect against Kleb-
siella isolates, was synergistic against 12 of 25 of these isolates (Fig. 2). Furthermore,
the combination of vancomycin and cephalothin was synergistic against 19 of these
25 isolates. However, the combination of carbenicillin and cephalothin produced
unexpected results. This antibiotic combination resulted in synergistic activitySYNERGY BY SEQUENTIAL BLOCKING WITH VANCOMYCIN
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against 16 of the 25 isolates studied (Fig. 2). The combination of vancomycin and
carbenicillin was synergistic against 19 of the 25 isolates of Serratia marcescens
(Table 2 and Fig. 2). Similar results were observed with the combination ofvancomy-
cin and cephalothin which produced a synergistic effect in 15 of 25 Serratia isolates
(Fig. 2). In contrast, the combination ofcarbenicillin and cephalothin, two antibiot-
ics which inhibit the same metabolic site of the bacterial cell, not only produced no
synergy but resulted in a partially antagonistic effect in 14 of the 25 isolates of
Serratia studied (Table 3 and Fig. 2). A summary of the results of each of the three
antibiotic combinations against the twenty-five isolates each of Pseudomonas, Kleb-
siella, and Serratia is listed in Table 4. The carbenicillin-vancomycin and
cephalothin-vancomycin combinations had significantly more synergistic and partial
synergistic activity against Pseudomonas isolates than the combination ofcarbenicil-
lin and cephalothin, and the incidence of synergy and partial synergy was not
significantly higher when vancomycin was combined with carbenicillin rather than
cephalothin (Table 4). In contrast, the incidence of synergy and partial synergy was
not significantly different among these three combinations ofantibiotics when tested
against Klebsiella isolates (Table 4). However, the carbenicillin-vancomycin and
cephalothin-vancomycin combinations were also significantly more synergistic and
partially synergistic against Serratia isolates than the combination of carbenicillin-
cephalothin. In addition, the incidence of synergy and partial synergy was not
significantly higher when vancomycin was combined with carbenicillin rather than
cephalothin (Table 4). Further analysis comparing the carbenicillin-sensitive (0.625
to 15.6 ug/ml) and carbenicillin-resistant (2500 to 10,000 ug/ml) isolates of Serratia
(Table 1) revealed no significant difference in the incidence of synergy and partial
synergy for the carbenicillin-vancomycin combination. Thus, vancomycin and carbe-
nicillin produced a similar incidence of synergy and partial synergy regardless of
whether the Serratia isolates were sensitive or resistant to carbenicillin (Table 2). A
significant difference (p < 0.05) however, was observed in the incidence of partial
antagonism in the carbenicillin-cephalothin experiments (Table 3). The results show
169170 . DONABEDIAN AND ANDRIOLE
TABLE 2
Minimal Inhibitory Concentrations of
Carbenicillin and Vancomycin Alone and in Combination
Against Twenty-five Strains of Serratia
Strain No. Carbenicillin Carbenicillin + Vancomycin Vancomycin
(4g/ml) Lowest MIC* (4g/ml) (Ag/ml)
Synergy
1009
1011
1122
782
798
800
802
980
996
1115
1117
1120
Partial
Synergy
1125
1126
1127
1130
698
720
1121
Additive
756
759
Indifferent
758
1124
1128
1123
2.5
7.8
15.6
5000
10,000
10,000
10,000
5000
5000
10,000
10,000
10,000
S
7.8
7.8
2500
5000
10,000
2.5
0.625
0.625
2.5
2.5
2500
0.312
1.95
1.95
156
156
156
156
156
156
156
156
156
2.5
2.5
3.9
1.95
312
156
156
2500
1250
625
1250
1250
625
625
312
625
2500
2500
1250
>5000
>5000
>5000
5000
5000
5000
5000
>5000
5000
>5000
>5000
5000
312
78
625
1250
625
1250
2500
2500
1250
2500
2500
1250
2500
5000
2500
2500
1250
1250
2500
2500
*Lowest MIC listed is the lowest concentration of each antibiotic at which synergy or partial synergy can be seen.
Carbenicillin-sensitive strains of Serratia are listed first in each category, followed by the carbenicillin-resistant strains.
that the carbenicillin-sensitive strains are significantly more likely to be antagonized
by cephalothin than are the carbenicillin-resistant strains. This may simply reflect the
marked differences in the concentration ofcarbenicillin in the two groups whereas the
concentration ofcephalothin in both groups was similar, that is, the concentration of
cephalothin relative to the concentration of carbenicillin was much greater for the
carbenicillin-sensitive strains than for the carbenicillin-resistant isolates of Serratia.
This concentration difference may well facilitate any postulated interference of
carbenicillin by cephalothin.
DISCUSSION
The results of the present study demonstrate that the addition of vancomycin to
either carbenicillin or cephalothin results in significant synergistic activity against
isolates of Pseudomonas or Serratia as compared to the activity ofthe combination
of carbenicillin and cephalothin. These observations would appear to support the
theory that the potential for synergistic activity can be predicted for antibioticSYNERGY BY SEQUENTIAL BLOCKING WITH VANCOMYCIN 171
TABLE 3
Minimal Inhibitory Concentrations of
Carbenicillin and Cephalothin Alone and in Combination
Against Twenty-five Strains of Serratia
Strain No. Carbenicillin Carbenicillin + Cephalothin Cephalothin
(Ag/ml) Highest MIC* (pg/ml) (Ag/ml)
Partial
Antagonism
756
758
759
1009
1011
1122
1124
1125
1126
1127
1128
698
720
782
Indifferent
1130
798
800
802
980
996
1115
1117
1120
1121
1123
6.25
1.56
0.78
6.25
6.25
12.5
6.25
6.25
3.12
12.5
6.25
1250
2500
2500
12.5
12.5
12.5
12.5
12.5
12.5
12.5
12.5
12.5
12.5
12.5
5000
5000
5000
5000
5000
5000
5000
5000
5000
5000
5000
5000
5000
5000
2500
5000
5000
10,000
10,000
10,000
10,000
10,000
10,000
10,000
10,000
10,000
10,000
10,000
10,000
10,000
10,000
25
10,000
10,000
10,000
10,000
10,000
10,000
10,000
10,000
10,000
10,000
10,000
10,000
5000
10,000
10,000
10,000
10,000
10,000
10,000
10,000
10,000
*Highest concentration listed is the highest concentration of each antibiotic at which there is partial antagonism. For
example, strain #756 has no inhibition of growth at 12.5 ug/ml of carbenicillin even though the minimal inhibitory
concentration ofcarbenicillin alone is 6.25 ug/ml. Carbenicillin-sensitive strains are listed first ineach category, followed
by the carbenicillin-resistant strains.
combinations which block sequential sites, i.e., successive stages of the bacterial
biosynthetic pathway [9]. The use of sequentially acting antibiotics to produce
synergy has been observed previously with the combination of trimethoprim-
sulfamethoxazole which blocks two successive stages ofbacterial folic acid synthesis
[10]. The present study was designed to evaluate sequential blockage ofmurein cell
wall synthesis of some gram-negative bacilli although other biosynthetic pathways
such as ribosomal protein synthesis, could have been investigated by otherantibiotic
combinations.
Each species of bacteria has its own particular cell wall composition. All gram-
negative cell walls are complex in theircomposition, but allcontain amurein cell wall
component. In gram-negative bacteria, the murein component makes up about 10%
ofthe dry weight ofthe cell wall. The murein component in all bacteria is made up of
polymers of alternating N-acetyl glucosamine (NAG) and N-acetyl muramic acid
(NAM) in a beta 1,4 linkage (Fig. 1). Attached to each NAM residue is a chain of a
few (usually four) amino acids. These amino acid chains are cross-linked bytranspep-
tidation to form the lattice work of the polymer chains that is the murein cell wall.172 DONABEDIAN AND ANDRIOLE
TABLE 4
The Effect of Antibiotic Combinations on
Twenty-five Isolates each of Pseudomonas, Klebsiella and Serratia
Antibiotic
Combination* Synergy Partial Synergy Additive Indifferent
Pseudomonas
C + V 7t (28%) 12 (48%) 5 (20%) 1 (4%)
K + V 0 12 (48%) 6 (24%) 7 (28%)
C + K 0 4 (16%) 5 (20%) 16 (64%)
Carbenicillin-vancomycin vs carbenicillin-cephalothin p<0.01
Cephalothin-vancomycin vs carbenicillin-cephalothin p<0.05
Carbenicillin-vancomycin vs cephalothin-vancomycin NS§
Klebsiella
C + V 0 12 (48%) 7 (28%) 6 (24%)
K + V 2 (8%) 17 (68%) 6 (24%) 0
C + K 2 (8%) 14 (56%) 7 (28%) 2 (8%)
Carbenicillin-vancomycin vs carbenicillin-cephalothin NS
Cephalothin-vancomycin vs carbenicillin-cephalothin NS
Carbenicillin-vancomycin vs cephalothin-vancomycin NS
Serratia
C + V 12 (48%) 7 (28%) 2 (8%) 4 (16%)
K + V 11 (44%) 4 (16%) 5 (20%) 5 (20%)
Partial antagonism Indifferent
C + K 14 (56%) 11 (44%)
Carbenicillin-vancomycin vs carbenicillin-cephalothin p<0.01
Cephalothin-vancomycin vs carbenicillin-cephalothin p<0.01
Carbenicillin-vancomycin vs cephalothin-vancomycin NS
*V = Vancomycin C = Carbenicillin K= Cephalothin
tNumber of isolates
§NS = no significant difference
The general scheme of murein synthesis includes the following steps (Fig. 1): (1) N-
acetyl muramic acid is attached to a uridine diphosphate carrier; (2) the amino acid
chain is built upon the NAM residue to form the UDP-NAM-peptide unit. The
peptide chain invariably has as its two terminal amino acids D alanine and Dalanine;
(3) the NAM-peptide unit is transferred from the UDP to a lipid diphosphate carrier;
(4) an N-acetyl glucosamine unit is added to the NAM to form the lipid-NAG-NAM-
peptide peptidoglycan subunit; (5) the peptidoglycan subunit is transferred from the
lipid carrier inside the cell to the cell wall outside the cell; (6) the free amino acid side
chains are cross-linked to each other through transpeptidation to form a network. In
cross-linking, the D alanine at the end of the amino acid chain is hydrolyzed offthe
peptide. There is variation in the number and types ofamino acids in the peptide side
chains and the method of transpeptidation depending on the bacterial species.
However, all the species studied have two D alanine residues as the terminal amino
acids in the peptidoglycan subunits. These two D alanines are the key to the action of
vancomycin.
There is good evidence that the penicillins and the cephalosporins both act at the
same site in cell wall synthesis [11-13]. That site is the final transpeptidation of the
peptide side chains. The site of vancomycin's action is not absolutely defined, but
there is good evidence that vancomycin binds to the D-alanine configuration ofcell
wall subunit precursors [14-16] and inhibits the incorporation of fully formedSYNERGY BY SEQUENTIAL BLOCKING WITH VANCOMYCIN
subunits into the cell wall [15] of both gram-negative and gram-positive species. A
series of studies using isolated intermediates and artificially prepared peptides
showed that vancomycin combined specifically with intermediates and peptides with
the terminal D alanine D alanine configuration [14-16]. Artificially synthesized
peptides with terminal D alanine D alanine will bind vancomycin veryeffectively and
block vancomycin's in vivo effect on several bacterial species. The binding can be
followed spectrophotometrically and is quite strong. There is detectable binding in 8
M urea, 4 M KCI, and 1% sodium dodecyl sulfate. The binding occurs at a pH range
of four to nine. The binding also occurs with UDP-NAM-peptide, NAM-peptide,
and the peptide alone. A precursor UDP-NAM-peptide without the terminal D
alanine D alanine amino acids had no vancomycin binding. Vancomycin was also
shown to be almost completely bound to the cell wall, with very little entering the cell
itself [17]. In these studies, Nieto and Perkins elucidated the binding ofvancomycin
to both UDP-NAM-peptide and cell walls. Labelled vancomycin 1125 was used to
study its binding activity with various substrates. Whole cells of M. lysodeikticus
were used in 10 ug/ml vancomycin. Within three minutes 75% of all the labelled
antibiotic was recoverable on the cell walls. When cell wall-free protoplasts were
used, less than 2% of the vancomycin was taken up by the cells [17]. Further work
[18] indicated that vancomycin does not act effectively at the penicillins or the
cephalosporins site of action. Thus, there is good evidence that vancomycin acts in
vivo to prevent the transfer of the NAG-NAM-peptide subunit from the lipid carrier
to the cell wall and that this is the primary site of vancomycin action. Therefore,
vancomycin is a reasonable choice for studies of sequential blockage of steps in a
single pathway since it is known that penicillins and cephalosporins act by inhibiting
the last step ofcell wall synthesis, that ofcross-linking the peptides, whereas vancom-
ycin acts at a step prior to the action of both the penicillins and cephalosporins.
In the present studies, a representative penicillin, carbenicillin, was chosen because
it is effective against most strains of Pseudomonas and some strains of Serratia, but
usually ineffective against strains of Klebsiella. Cephalothin was chosen as the
cephalosporin because it is usually effective against strains of Klebsiella and usually
ineffective against strains of Pseudomonas and Serratia. Vancomycin was selected
because it is ineffective against strains of Pseudomonas, Klebsiella, and Serratia.
Furthermore, the experiments described in the present study used gram-negative
bacteria in order to see whether the synergy achieved would be sufficient to clinically
extend the use ofvancomycin to gram-negative bacillary infections. The results ofthe
present experiments support the model of sequential blockage as a basis for synergy.
The incidence of synergy and partial synergy, observed when vancomycin and
carbenicillin or vancomycin or cephalothin were combined against isolates of Pseu-
domonas and Serratia, was significantly higher than when carbenicillin and cephal-
othin were combined against these isolates. These observations suggest that underthe
conditions of the experiments, only those antibiotics which act sequentially produced
a significant incidence of synergy and partial synergy. It is particularly interesting to
note that there was no significant difference in the incidence of synergy and partial
synergy in the Pseudomonas and Serratia studies regardless ofwhether the bacteria
were sensitive or resistant to the drug added to vancomycin. The Pseudomonas
isolates studied had essentially the same incidence ofsynergy and partial synergywith
the combination of vancomycin and carbenicillin as with the combination of van-
comycin and cephalothin. This was observed even though these Pseudomonas
isolates were sensitive to carbenicillin and highly resistant to cephalothin. Further-
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more, when the carbenicillin-sensitive and carbenicillin-resistant strains of Serratia
were analyzed separately, there was no significant difference in the incidence of
synergy between these two groups oforganisms when tested against the carbenicillin-
vancomycin combination. These data further support the model of sequential action
regardless of whether the organisms are sensitive or resistant to one ofthe antibiotics.
These observations are in contrast to those of Baltimore and colleagues [19] who
noted that synergy against Klebsiella isolates was related to the susceptibility ofthe
isolates to one of the antibiotics in the combination studied. We have no obvious
explanation for this difference except to suggest that it may be related to the bacterial
species.
In contrast to the results observed in the present study with isolates ofPseudomo-
nas and Serratia, there was no significant difference in the incidence of synergy and
partial synergy among the three combinations of antibiotics when tested against
isolates of Klebsiella species. The incidence of synergy observed against Klebsiella
with the combination of vancomycin and carbenicillin as well as with vancomycin
and cephalothin was not significantly greater than that observed with the combina-
tion of carbenicillin and cephalothin. Since carbenicillin and cephalothin act at the
same site in the pathway of cell wall biosynthesis, the model does not predict this
degree of synergy with the combination. We have no clear explanation for this
observation. Further work is needed to explain why there should be synergy and
partial synergy with the carbenicillin-cephalothin combination when these antibiotics
act at the same site. One possible explanation may lie in the prevalence ofpenicillin-
degrading enzymes produced by gram-negative bacteria. Rollinson [20] showed that
many enterobacteria produce various types of enzymes which degrade penicillin and
would presumably degrade carbenicillin. If carbenicillin resistance in Klebsiella is
conferred by an enzyme which degrades carbenicillin and if cephalothin interferes
with this carbenicillin degradation, then the presence of cephalothin might increase
the efficacy of carbenicillin and thus lead to synergy. Several studies [21-25] have
shown that beta lactamase inhibitors such as oxacillin can inhibit enzymes that
degrade penicillins and cephalosporins. These studies indicate that synergy could be
obtained in many cases ofgram-negative organisms which are resistant to penicillins
or cephalosporins by combination of cephalosporins or penicillins with such beta
lactamase inhibitors as oxacillin and methicillin. Since cephalothin can inhibit some
lactamases, it is not unreasonable to suppose that it might inhibit certain enzymes
produced by Klebsiella which degrade carbenicillin. Anotherpossible explanation for
the synergy observed against Klebsiella isolates, in the present study, with the
carbenicillin-cephalothin combination may be the mechanism recently described by
Poe [26]. In these latter studies sulfonamides were shown to be moderately potent
inhibitors of bacterial dihydrofolate reductase and provide some basis for a new
theory of synergy. Specifically, the mechanism for the synergistic activity observed
with the combination oftrimethoprim and sulfamethoxazole has been thought to be
based on sequential inhibition of the bacterial cell with trimethoprim inhibiting
dihydrofolate reductase and sulfamethoxazole competing with para-aminobenzoic
acid. Poe's [26] experiments, however, suggest that synergistic dose-response curves
can be obtained in vitro by the action of two inhibitors on a single enzyme, i.e.,
multiple simultaneous inhibitors of bacterial dihydrofolate reductase by the sulfon-
amides and trimethoprim acting together. The possibility exists that carbenicillin and
cephalothin may produce a synergistic effect against Klebsiella bymultiple simultane-
ous inhibition oftranspeptidation. However, we did not see a similar effect with this
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combination when tested against Pseudomonas or Serratia isolates, nor did we do
any experiments to investigate this possible mechanism of action against Klebsiella
isolates.
Although the present observations support, in general, the hypothetical model of
antibiotic synergy based on sequential blocking ofone biochemical pathway, another
mechanism of synergy must also be considered. Namely, one of the antibiotics in the
combination might increase the penetration into the cell ofthe other antibiotic. This
mechanism has been shown to be responsible for the antibiotic synergy observed with
the combination of penicillin and streptomycin against enterococci [26]. However,
this explanation is not likely to be responsible for the present observations because
earlier studies by Perkins and Nieto [17], demonstrated that the uptake of vancomy-
cin into the cytoplasm of bacteria without cell walls is only slightly greater than the
uptake of vancomycin by bacteria with complete cell walls. Finally, although the
synergistic and partially synergistic combinations developed in the present study
require concentrations ofvancomycin which are not clinically achievable in man, the
results observed do support the model of sequential action. This theoretical basis of
action can predict synergy and therefore can be used to investigate both old and new
antibiotics in an attempt to develop synergistic combinations which may in the future
be clinically useful.
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